| Name | Vonoprazan Fumarate |
| Description | Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5. |
| In vitro | The inhibitory activity of Vonoprazan Fumurate was unaffected by ambient pH. The inhibition by Vonoprazan Fumurate was reversible and achieved in a K(+)-competitive manner, quite different from that by lansoprazole. Vonoprazan Fumurate exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner[4]. |
| In vivo | Vonoprazan Fumurate, at a dose of 4 mg/kg (as the free base) orally, completely inhibited basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats, and its effect on both was stronger than that of lansoprazole. Vonoprazan Fumurate increased the pH of gastric perfusate to a higher value than did lansoprazole or SCH28080, and the effect of Vonoprazan Fumurate was sustained longer than that of lansoprazole or SCH28080[4]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.62 mg/mL (10.01 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.17 mM), Sonication is recommended.
|
| Keywords | Vonoprazan Fumarate | Vonoprazan | ulcer | T2404 | secretion | reflux | pump | Protonpump | Proton pump | proton | potassium | peptic | P-CAB | inhibitor | inhibit | GERD | gastroesophageal | gastric | disease | competitive | blocker | antisecretory | acid |
| Inhibitors Related | Abscisic Acid | Rabeprazole Sulfide | FR-167356 | Omeprazole | Chebulinic acid | Esomeprazole | Pantoprazole sodium | Esomeprazole Magnesium | Pantoprazole Sodium Hydrate | Lansoprazole | Zinc pyrithione | Esomeprazole Sodium |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
